Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5261-5272

  Zhang, Wanying ^a   Li, Haonan ^a   Dong, Hua ^b   Liao, Jie ^a   Hammock, Bruce D ^b   Yang, Guang Yu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinogenesis; Colitis; Dextran sulfate sodium; Mice; Soluble epoxide hydrolase

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDIC ACID; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DIHYDROEICOSATRIENOIC ACID; DIHYDROXYOCTADECENOIC ACID; EPOXIDE HYDROLASE; EPOXYOCTADECENNOIC ACID; GAMMA INTERFERON; ICOSANOID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; LIPOXYGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN D2; PROSTAGLANDIN E2; SOLUBLE EPOXIDE HYDROLASE; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CANCER SIZE; COLLOID CARCINOMA; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; ENZYME DEFICIENCY; EPOXIDE HYDROLASE DEFICIENCY; GASTROINTESTINAL DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LAMINA PROPRIA; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBMUCOSA; TISSUE MICROARRAY; ULCERATIVE COLITIS;

EID: 84891408718     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Maloy KJ: The Interleukin-23/interleukin-17 axis in intestinal inflammation. J Intern Med 263(6): 584-590, 2008.
2. Coussens LM and Werb Z: Inflammation and cancer. Nature 420(6917): 860-867, 2002.
3. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, and Ullman T: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133(4): 1099-1105, 2007.
4. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, and Forbes A: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126(2): 451-459, 2004.
5. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L and O'Shea JJ: Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103(21): 8137-8142, 2006.
6. Jess T, Rungoe C, and Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10(6): 639-645, 2012.
7. Vidailhet M: Omega 3: is there a situation of deficiency in young children?. Arch Pediatr 14(1): 116-123, 2007.
8. Schaad NC, Magistretti PJ and Schorderet M: Prostanoids and their role in cell-cell interactions in the central nervous system. Neurochem Int 18(3): 303-322, 1991.
9. Morisseau C and Hammock BD: Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health. Annu Rev Pharmacol Toxicol 53: 37-58, 2013.
10. Norwood S, Liao J, Hammock BD and Yang GY: Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res 2(4): 447-457, 2010.
11. Zhang W, Liao J, Li H, Dong H, Bai H, Yang A, Hammock BD and Yang GY: Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency. Mol Carcinog 52(9): 726-38, 2013.
12. Morisseau C, Newman JW, Tsai HJ, Baecker PA and Hammock BD: Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett 16(20): 5439-5444, 2006.
13. Newman JW, Morisseau C, Harris TR and Hammock BD: The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci USA 100(4): 1558-1563, 2003.
14. Zhang W, Yang AL, Liao J, Li H, Dong H, Chung YT, Bai H, Matkowskyj KA, Hammock BD and Yang GY: Soluble Epoxide Hydrolase Gene Deficiency or Inhibition Attenuates Chronic Active Inflammatory Bowel Disease in IL-10(-/-) Mice. Dig Dis Sci 57(10): 2580-2591, 2012.
15. Coskun M, Olsen AK, Holm TL, Kvist PH, Nielsen OH, Riis LB, Olsen J and Troelsen JT: TNF-alpha-induced downregulation of CDX2 suppresses MEP1A expression in colitis. Biochim Biophys Acta 1822(6): 843-851, 2012.
16. Hokari R, Kurihara C, Nagata N, Aritake K, Okada Y, Watanabe C, Komoto S, Nakamura M, Kawaguchi A and Nagao S: Increased expression of lipocalin-type-prostaglandin D synthase in ulcerative colitis and exacerbating role in murine colitis. Am J Physiol Gastrointest Liver Physiol 300(3): G401-408, 2011.
17. Tuin A, Poelstra K, de Jager-Krikken A, Bok L, Raaben W, Velders MP and Dijkstra G: Role of alkaline phosphatase in colitis in man and rats. Gut 58(3): 379-387, 2009.
18. Liao J, Seril DN, Yang AL, Lu GG and Yang GY: Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. Carcinogenesis 28(2): 446-454, 2007.
19. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C and Mukaida N: Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118(2): 560-570, 2008.
20. Seril DN, Liao J, Ho KL, Warsi A, Yang CS and Yang GY: Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci 47(6): 1266-1278, 2002.
21. Seril DN, Liao J, Ho KL, Yang CS and Yang GY: Inhibition of chronic ulcerative colitis-associated colorectal adenocarcinoma development in a murine model by N-acetylcysteine. Carcinogenesis 23(6): 993-1001, 2002.
22. Seril DN, Liao J and Yang GY: Colorectal carcinoma development in inducible nitric oxide synthase-deficient mice with dextran sulfate sodium-induced ulcerative colitis. Mol Carcinog 46(5): 341-353, 2007.
23. Talero E, Sanchez-Fidalgo S, Villegas I, de la Lastra CA, Illanes M and Motilva V: Role of different inflammatory and tumor biomarkers in the development of ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis 17(3): 696-710, 2011.
24. Sanchez-Fidalgo S, Villegas I, Cardeno A, Talero E, Sanchez-Hidalgo M, Motilva V and Alarcon de la Lastra C: Extravirgin olive oil-enriched diet modulates DSS-colitisassociated colon carcinogenesis in mice. Clin Nutr 29(5): 663-673, 2010.
25. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW and Hammock BD: Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282(5): 2891-2898, 2007.
26. Enayetallah AE, French RA, Barber M and Grant DF: Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J Histochem Cytochem 54(3): 329-335, 2006.
27. Enayetallah AE, French RA and Grant DF: Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol 37(3-4): 133-141, 2006.
28. Roques M, Bagrel D, Magdalou J and Siest G: Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione Stransferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells. Gen Pharmacol 22(4): 677-684, 1991.
29. Yang MD, Wu CC, Chiou SH, Chiu CF, Lin TY, Chiang IP and Chow KC: Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma. Oncol Rep 10(2): 271-276, 2003.
30. Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, Rossi G, Pedroni M, Luppi D, Santoro L and Monni S: Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17(9): 2291-2297, 2008.
31. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE and Busse R: Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88(11): E68-75, 2001.
32. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N and Hammock BD: Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79(6): 880-887, 2010.
33. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD and Imig JD: Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297(3): F740-748, 2009.
34. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC and Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285(5431): 1276-1279, 1999.
35. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP and Hammock BD: Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102(28): 9772-9777, 2005.
36. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP and Hammock BD: Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103(37): 13646-13651, 2006.
37. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnes CM, Mammoto A, Mammoto T and Luria A: Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 122(1): 178-191, 2012.
38. Cui PH, Petrovic N and Murray M: The omega-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 downregulation. Br J Pharmacol 162(5): 1143-1155, 2011.
39. Fleming I: The cytochrome P450 pathway in angiogenesis and endothelial cell biology. Cancer Metastasis Rev 30(3-4): 541-555, 2011.
40. Panigrahy D, Greene ER, Pozzi A, Wang DW and Zeldin DC: EET signaling in cancer. Cancer Metastasis Rev 30(3-4): 525-540, 2011.